HA-02. Genetic mutations in children with acquired aplastic anemia

Cellular Therapy and Transplantation

article

Irma V. Yemialyanova¹  Tatiana А. Uglova¹  Alexander А. Migas¹  Olga V. Aleinikova¹ 

[1] Belarusian Research Center for Pediatric Oncology

关键词: Severe aplastic anemia;    stratification;    molecular genetics;    allo-HSCT.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-3-1-132

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

The standard of treatment for pediatric patients with severe acquired aplastic anemia (SAA), who do not have an HLA-compatible related donor to perform allogeneic hematopoietic stem cell transplantation (HSCТ), is the combined immunosuppressive therapy (IST). An unsatisfactory result of IST motivates to search for factors that determine the need for allo-HSCT from an unrelated HLA-identical donor as first-line therapy. This retrospective study was designed in order to search for early unrelated donor allogeneic HSCT decision-making criteria in children with SAA.

【 授权许可】

CC BY